Pharma

Can Bagasse Turn Sugar Waste into Green Rhamnolipids?
Manufacturing Can Bagasse Turn Sugar Waste into Green Rhamnolipids?

Traditional surfactant production relies heavily on petroleum, yet microbial molecules derived from agricultural waste offer a biodegradable and low-toxicity alternative. The global sugar industry stands at a pivotal crossroads as it manages the staggering volume of byproducts generated by

Can Talent Solve the U.S. Pharma Reshoring Bottleneck?
Manufacturing Technology Can Talent Solve the U.S. Pharma Reshoring Bottleneck?

The federal government's 2024 proclamation imposing 100% tariffs on foreign-made patented drugs has forced a rapid and massive restructuring of the American pharmaceutical supply chain. This policy shift was designed to bolster national security, yet it has also triggered a frantic rush to

Biopharma CDMOs Must Modernize to Meet Rising Cost Pressures
Manufacturing Biopharma CDMOs Must Modernize to Meet Rising Cost Pressures

Kwame Zaire is a titan in the manufacturing world, renowned for bridging the gap between high-level production management and the intricate mechanics of biopharmaceutical supply chains. With a career dedicated to predictive maintenance and quality assurance, he has watched the industry shift from a

Is OEB 7 the New Standard for Ultra-Potent Drug Safety?
Management Is OEB 7 the New Standard for Ultra-Potent Drug Safety?

Precise dispensing and weighing must occur within a fully enclosed environment to prevent even the smallest toxicological consequences. As the pharmaceutical landscape of 2026 continues to shift toward highly targeted therapies, the industry is witnessing an unprecedented surge in the development

How Does Advanced Technology Drive Global Pharma Expansion?
Management How Does Advanced Technology Drive Global Pharma Expansion?

The successful qualification for global humanitarian programs was predicated on the ability to minimize process variability through sophisticated granulation technology. For regional pharmaceutical entities like Beta Pharmacon, the aspiration to reach international markets required a departure from

Can Radiopharma Infrastructure Keep Up With Clinical Growth?
Manufacturing Can Radiopharma Infrastructure Keep Up With Clinical Growth?

As we navigate the midpoint of this decade, the pharmaceutical manufacturing landscape is undergoing a profound transformation driven by the rise of targeted radioligand therapies. This "inside-out" approach to oncology is no longer a niche experimental field; it has become a multi-billion dollar

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later